

CytoReason expands reach in Asia, leveraging ML in drug development for Korean drugmakers

13 April 2022 | News

Forging commercial alliance with Helixrus to leverage machine learning (ML) in drug development



Israel's CytoReason, a leading developer of computational disease models for efficient drug discovery and development, has announced the signing of a commercial partnership with Helixrus, a leading Korean company focused on biological big data and multi-omics. The partnership will see Helixrus represent CytoReason's unique AI platform and professional services in the Korean market.

CytoReason has established itself as a global leader in computational modeling of human diseases. The company's multidisciplinary team of 65 leading biologists, bioinformaticians and data engineers has developed a technology that enables pharma and biotech companies to speed up drug R&D and bring novel therapies to the patients who most need them.

The alliance will focus on leveraging Helixrus' deep knowledge of the Korean pharmaceutical market, and extensive network of relationships in Asian markets, to highlight CytoReason's capabilities in prioritizing new targets, finding biomarkers, profiling combinations, stratifying patients, and other use cases within the drug lifecycle.

CytoReason has existing collaborations with five of the world's largest pharmaceutical companies, including Pfizer and Sanofi. Its proprietary platform has yielded a range of clinically validated results in multiple diseases.